A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod PH20 SC in Adults With Pemphigus (Vulgaris or Foliaceus)

Stopped Based on the lack of observed efficacy in the primary study ARGX-113-1904, the sponsor decided to discontinue the open-label extension study.

Conditions

• Pemphigus Vulgaris
• Pemphigus Foliaceus

Interventions

• BIOLOGICAL: efgartigimod PH20 SC
• DRUG: prednisone

Sponsor

argenx